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The pharmacokinetics and dosage regimen of cefotaxime
following its single subcutaneous administration (10 mg/
kg) were investigated in buffalo calves. Plasma and urine
samples were collected over 10 and 24 h post administration,
respectively. Cefotaxime in plasma and urine was estimated
by microbiological assay technique using E. coli as test
organism. The pharmacokinetic profiles fitted one-compartment
open model. The peak plasma levels of cefotaxime were
6.48 ± 0.52 µg/ml at 30 min and the drug was detected
upto 10 h. The absorption half-life and elimination half-
life were 0.173 ± 0.033 h and 1.77 ± 0.02 h, respectively.
The apparent volume of distribution and total body
clearance were 1.17 ± 0.10 l/kg and 0.45 ± 0.03 l/kg/h,
respectively. The urinary excretion of cefotaxime in 24 h,
was 5.36 ± 1.19 percent of total administrated dose. A
satisfactory subcutaneous dosage regimen for cefotaxime
in buffalo calves would be 13 mg/kg repeated at 12 h
intervals.
Key words: buffalo calf, cefotaxime, dosage regimen, phar-
macokinetics
Introduction
Cefotaxime was the first of the third generation cephalosporins
to be released in the market. It is broad spectrum antibiotic
and highly resistant to the action of β-lactamase enzyme.
Against gram negative micro organisms, it exhibits greater
in vitro activity than any of the previous cephalosporins [14].
Pharmacokinetic studies of antimicrobial agents, which
provide a basis for the determination of their satisfactory
dosage regimen, are relevant when they are undertaken in
the species in which the drugs are to be used clinically. The
pharmacokinetics of cefotaxime have been investigated in
humans [11], rats [10], Sheep [8,9], dogs [7], cats [13], goats
[2,5] cattle [16,17] and buffaloes [18]. The purpose of this
study was to determine the pharmacokinetics, urinary excretion
and appropriate dosage regimen of cefotaxime in buffalo
calves after a single subcutaneous administration. Recently,
in Veterinary practice, administration of antibiotics by
subcutaneous route has been found very effective [4].
Materials And Methods
Five healthy male buffalo calves ranging between 1 and
1.5 years of age with an average weight of 91 kg were used
in the present study. The animals were kept in the departmental
animal shed with concrete floor and adequate ventilation. A
constant supply of water was maintained in the shed. All the
animals were acclimatized in the animal shed under uniform
conditions and were maintained on green fodder and wheat
straw and water ad libitum. On the day of experiment, the
animals were kept in standard metabolic stalls, designed so
that all the urine passed by the animals over a particular
period could be collected without any contamination or
spillage. Cefotaxime Sodium (Claforan; Hoechst Marion
Roussel, India) was given by subcutaneous route at the dose
rate of 10 mg/kg body weight as a 10% freshly prepared
solution in sterilized distilled water. Blood samples (5 ml
each) were withdrawn from the jugular vein into heparinized
glass test tubes before administration and at 1, 2.5, 5, 7.5, 10,
15, 20, 30, 45, 60 and 90 min and 2, 3, 4, 5, 6, 7, 8 and 10 h
after administration of the drug. Plasma was collected after
centrifugation at 2000 × g for 15 min at room temperature
and kept at –20
oC until analysis, usually the next day. The
urine samples were collected at 4, 8, 12, 16, 20 and 24 h
after drug administration. The volume of urine was measured
and approximately 8-10 ml was frozen for drug analysis.
The concentration of cefotaxime in the plasma and urine
were estimated by employing the microbiological assay
technique [1,19] using Escherichia coli (ATCC 25922) as
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the test organism. The assay could detect a minimum of 0.1
µg/ml of cefotaxime. The standard curve of cefotaxime in
buffalo calf plasma was linear between 0.1 to 0.6 µg/ml. The
value of correlation coefficient (r) was 0.99. The plasma
concentration - time data for each buffalo calf were determined
according to the computed least squares regression
technique. The kinetic parameters were calculated from the
formulae derived for a one - compartment open model
[6,15]. Based on the kinetic data, the dosage regimen of
cefotaxime were also determined [3].
Results
The mean plasma concentrations of cefotaxime as a function
of time were plotted on a semilogarithmic scale (Fig. 1). At
2.5 min, after subcutaneous administration, the mean plasma
concentration was 0.60 ± 0.05 µg/ml. The peak drug
concentration of 6.48 ± 0.52 µg/ml was achieved at 30 min
of injection which gradually declined to 0.12 ± 0.01 µg/ml
at 10 h.
The various pharmacokinetic parameters are presented in
Table 1. The absorption half-life and elimination half-life
were 0.173 ± 0.033 h and 1.77 ± 0.02 h, respectively. The
apparent volume of distribution and total body clearance
were 1.17 ± 0.10 l/kg and 0.45 ± 0.03 l/kg/h, respectively.
Table 2 summarizes the urine concentration and extent of
urinary excretion cefotaxime in buffalo calves. At the end of
24 h, the urinary excretion of cefotaxime was 5.36% of total
administered dose. Taking 8 and 12 h as convenient dosage
intervals (t), with minimum therapeutic plasma concentration
[Cp (min)
∞] of 0.05, 0.1, 0.2, 0.4 and 0.6 µg/ml and using
the values of β and Vd(area) of Table 1, the dosage regimens
for cefotaxime were computed and are presented in Table 3.
Discussion
Evaluation of the results on observed plasma levels of
cefotaxime indicated that the data can be best fitted to one-
Fig. 1. Semilogarithmic plot of plasma concentration-time profile
of cefotaxime in buffalo calves following a single subcutaneous
dose of 10 mg/kg body weight. Values given are mean ± SE of 5
animals.
Table 1. Pharmacokinetic parameters of cefotaxime in buffalo
calves (n = 5) after a single subcutaneous dose of 10 mg/kg body
weight
Parameter Unit Mean ± SE
A* µg/ml 6.90 ± 0.45
Ka /h 4.61 ± 0.93
t½Ka h 0.173 ± 0.033
B µg/ml 6.33 ± 0.53
β /h 0.392 ± 0.004
t½β h 1.77 ± 0.02
AUC µg.h/ml 14.3 ± 0.91
AUMC µg.h
2/ml 40.5 ± 2.80
Vd(area) l/kg 1.17 ± 0.10
Vd(B) l/kg 1.63 ± 0.15
ClB l/kg/h 0.45 ± 0.03
MRT h 2.83 ± 0.05
td h 9.97 ± 0.09
Note: Kinetic parameters are as described by Gibaldi and Perrier (1982).
A* and B = Zero-time plasma drug concentration intercept of the
regression line of absorption and elimination phases, respectively; Ka
and β are the absorption and elimination rate constants, respectively; t ½Ka
= absorption half-life; t ½β = elimination half-life; AUC = area under the
plasma concentration-time curve; AUMC = area under the first-moment
curve; Vd(area) = apparent volume of distribution based on AUC; Vd (B) =
Volume of distribution based on zero-time plasma drug concentration
intercept of elimination phase; Cl B = total body clearance; MRT = mean
residence time; td = duration of therapeutic plasma concentration.
Table 2. Urine concentration and urinary excretion of cefotaxime
in buffalo calves after a single subcutaneous dose of 10 mg/kg
body weight
Time interval
(h)
Conc.
(µg/ml)
Percent of
total dose excreted
0-4 14.3 ± 9.71 0.12 ± 0.09
4-8 27.2 ± 11.9 1.40 ± 1.09
8-12 54.2 ± 18.8 2.84 ± 1.11
12-16 29.6 ± 12.4 2.40 ± 1.25
16-20 3.67 ± 1.87 0.38 ± 0.14
20-24 1.45 ± 0.46 0.04 ± 0.02
0-24 - 5.36 ± 1.19
The values given are mean ± SE of the results obtained from 3-5 animals.Subcutaneous pharmacokinetics and dosage regimen of cefotaxime in buffalo calves ( Bubalus bubalis)1 2 1
compartment open model with the exponential equation
C p=B e
−βt−A
1e
−Kat, where Cp is the cefotaxime concentration
at time t, A
1 and B are zero-time intercepts of absorption and
elimination phases of the plasma concentration-time curves,
respectively, Ka and β are the absorption and elimination
rate constants, respectively, and e represents the base of
natural logarithms.
The minimum therapeutic plasma concentration was
maintained from 2.5 to 10 h. The minimum inhibitory
concentration (MIC90) of cefotaxime has been reported to be
0.016-1 µg/ml [12]. The rapid appearance of cefotaxime in
the plasma suggests that this drug quickly enters into the
systemic circulation following subcutaneous administration,
and this is further confirmed by the high value for the
absorption rate constant (4.61 ± 0.93/h).
The elimination half-life of cefotaxime in buffalo calves
was 1.77 ± 0.02 h, which was shorter than its half-life in
cow calves, but longer than that reported in cats, dogs, sheep
and goats. The elimination half-lives of cefotaxime in cow
calves [17], cats [13], dogs [7], sheep [9] and goats [2] have
been reported to be 3.48, 0.98, 0.74, 0.38 and 0.36 h,
respectively. The total body clearance of cefotaxime in
buffalo calves is calculated to be 0.45 ± 0.03 l/kg/h, which is
lesser than from the data reported in cattle, dogs and sheep.
The values of total body clearance (Cl B) in cattle [17], dogs
[7] and sheep [9] have been calculated to be 0.81, 0.63 and
0.65 l/kg/h respectively. The total body clearance of
cefotaxime in cat [13] has been reported to be 0.17 l/kg/h,
which is approximately 2.5 fold lower than the values in
buffalo calves calculated in the present study. The results of
the present study revealed marked species differences in the
pharmacokinetic behaviour of cefotaxime.
In the present study, 5.36 ± 1.19 percent of the total
administered dose of cefotaxime was recovered in urine of
buffalo calves within 24 h. Similar result was also reported
in crossbred calves, where approximately 4.5 percent of the
total administered dose of cefotaxime was recovered in
urine within 12 h [17].
The ultimate objective of the present study was to
determine a satisfactory subcutaneous dosage regimen of
cefotaxime in buffalo species. Judicious use of an antibiotic
is not based solely on its pharmacokinetic behaviour. It also
depends on its clinical efficacy. But it is also not axiomatic
to extrapolate the data of dosage regimen from one species
to other species of animal without conducting the detailed
pharmacokinetic study. A suitable dosage regimen for
cefotaxime in buffalo calves was computed from the kinetic
data of present study. The primary (D) and maintenance (D')
doses were calculated by following equations:
D = Cp (min)
∞. Vd(e
βτ)
D' = Cp (min)
∞. Vd(e
βτ−1)
In clinical practice, the most suitable dosage schedule of
cefotaxime for a minimum therapeutic plasma concentration
(Cp (min)
∞) of 0.1 µg/ml, would be 12.9 mg/kg followed by
12.8 mg/kg repeated at 12 h intervals or it would be 13 mg/
kg repeated at 12 h intervals.
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